Company Encyclopedia
View More
name
CG oncology
CGON.US
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc.
1.944 T
CGON.USMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking78/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-24.74%E
    • Profit Margin-6967.99%E
    • Gross Margin-1668.37%E
  • Growth ScoreB
    • Revenue YoY217.84%A
    • Net Profit YoY-92.41%E
    • Total Assets YoY32.12%A
    • Net Assets YoY28.11%A
  • Cash ScoreB
    • Cash Flow Margin-1.44%D
    • OCF YoY217.84%A
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio5.79%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    3 'Strong Buy' Stocks to Buy Today,12/23/2025, According to Top Analysts

    Top Wall Street analysts have given Strong Buy ratings to three stocks: CG Oncology (CGON), WhiteFiber (WYFI), and Arcellx (ACLX). CGON has a price target of $90 with an 81.79% upside, WYFI has a price target of $34 with a 92.74% upside, and ACLX has a price target of $100 with a 30.75% upside. All analysts covering these stocks have rated them as Buys in the last three months.

    Tip Ranks·
    US
    ACLX
    +0.75%
    US
    CGON
    +0.22%
    US
    WYFI
    -1.53%
    Tip Ranks·
    US
    ACLX
    +0.75%
    US
    CGON
    +0.22%
    US
    WYFI
    -1.53%

    CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating

    Analyst Sam Slutsky from LifeSci Capital maintains a Buy rating on CG Oncology (CGON) with a $90 target, citing the company's lead asset, cretostimogene, and its strong position in the NMIBC market. The therapy's dual mechanism and safety profile, along with strategic market plans, support the rating. Wedbush also initiated coverage with a Buy rating and a $70 target.

    Tip Ranks·
    US
    CGON
    +0.22%
    Tip Ranks·
    US
    CGON
    +0.22%

    CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages

    Shares of CG Oncology, Inc. (NASDAQ:CGON) have been given an average recommendation of "Moderate Buy" by fifteen analysts. The average twelve-month price target is $60.58. Recent analyst ratings include JPMorgan's "overweight" with a $47 target, HC Wainwright's "buy" with a $75 target, and Royal Bank of Canada's "outperform" with a $61 target. Insider transactions include sales by Directors James Mulay and Leonard E. Post. Institutional investors own 26.56% of the stock. CG Oncology reported Q3 earnings of ($0.57) per share and revenue of $0.16 million.

    Market Beat·
    US
    CGON
    +0.22%
    Market Beat·
    US
    CGON
    +0.22%

    Promising Data on CG Oncology’s Cretostimogene Justifies Buy Rating

    JonesTrading analyst Soumit Roy has reiterated a Buy rating for CG Oncology's stock due to promising data on their bladder cancer treatment, cretostimogene. The treatment has shown impressive results in high-grade non-muscle invasive bladder cancer, outperforming competitors and standard care options. Positive data readouts have addressed previous concerns, and ongoing trials are expected to further solidify its market position.

    Tip Ranks·
    US
    CGON
    +0.22%
    Tip Ranks·
    US
    CGON
    +0.22%

    Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market

    Alec Stranahan from Bank of America Securities maintains a Buy rating on CG Oncology, Inc., with a $60 price target, citing the potential of their drug, cretostimogene, in treating NMIBC. The drug shows promise in both BCG-naïve and BCG-unresponsive settings, comparable to existing treatments. Strategic plans and a favorable safety profile support the positive outlook. LifeSci Capital also maintains a Buy rating with a $90 target.

    Tip Ranks·
    US
    CGON
    +0.22%
    Tip Ranks·
    US
    CGON
    +0.22%
    © 2025 Longbridge｜Disclaimer